RMD logo

RMD
Resmed Inc.

2,035
Mkt Cap
$36.71B
Volume
1.68M
52W High
$293.81
52W Low
$199.92
PE Ratio
25.74
RMD Fundamentals
Price
$251.49
Prev Close
$249.65
Open
$248.66
50D MA
$268.46
Beta
0.81
Avg. Volume
1.07M
EPS (Annual)
$9.51
P/B
6.00
Rev/Employee
$485,502.55
Loading...
Loading...
News
all
press releases
Twin Capital Management Inc. Acquires 2,219 Shares of ResMed Inc. $RMD
Twin Capital Management Inc. boosted its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 59.0% in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·24h ago
News Placeholder
More News
News Placeholder
Sienna Gestion Grows Stake in ResMed Inc. $RMD
Sienna Gestion increased its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 10.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·2d ago
News Placeholder
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
Zacks·9d ago
News Placeholder
Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·10d ago
News Placeholder
ResMed (RMD) Q1 Earnings and Revenues Beat Estimates
ResMed (RMD) delivered earnings and revenue surprises of +2.41% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Zacks·11d ago
News Placeholder
Do Options Traders Know Something About ResMed Stock We Don't?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Zacks·13d ago
News Placeholder
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago
News Placeholder
GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring
GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.
Zacks·18d ago
News Placeholder
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
Zacks·19d ago

Latest RMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.